These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23319853)

  • 1. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study.
    Cantini F; Niccoli L; Cassarà E; Kaloudi O; Nannini C
    Biologics; 2013; 7():1-6. PubMed ID: 23319853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs.
    Perrotta FM; Addimanda O; Ramonda R; D'Angelo S; Lubrano E; Marchesoni A; Olivieri I; Punzi L; Salvarani C; Spadaro A
    Reumatismo; 2014 Nov; 66(3):208-14. PubMed ID: 25376955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A multicenter, double-blind, randomized, placebo-controlled clinical trial of etanercept treatment of Chinese patients with active ankylosing spondylitis].
    Huang F; Zhang J; Zheng Y; Xu JH; Li XF; Wu HX; Chen ZW; Zhao Z; Zhang YM
    Zhonghua Nei Ke Za Zhi; 2011 Dec; 50(12):1043-7. PubMed ID: 22333175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients.
    De Stefano R; Frati E; De Quattro D; Menza L; Manganelli S
    Clin Rheumatol; 2014 May; 33(5):707-11. PubMed ID: 24062201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
    Brandt J; Listing J; Haibel H; Sörensen H; Schwebig A; Rudwaleit M; Sieper J; Braun J
    Rheumatology (Oxford); 2005 Mar; 44(3):342-8. PubMed ID: 15561737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients.
    Lee SH; Lee YA; Hong SJ; Yang HI
    Clin Rheumatol; 2008 Feb; 27(2):179-81. PubMed ID: 17874173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose.
    Raffeiner B; Botsios C; Ometto F; Bernardi L; Stramare R; Todesco S; Sfriso P; Punzi L
    Clin Exp Rheumatol; 2015; 33(1):63-8. PubMed ID: 25535985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial.
    Dougados M; van der Heijde D; Sieper J; Braun J; Maksymowych WP; Citera G; Miceli-Richard C; Wei JC; Pedersen R; Bonin R; Rahman MU; Logeart I; Wajdula J; Koenig AS; Vlahos B; Alvarez D; Bukowski JF
    Arthritis Rheumatol; 2014 Aug; 66(8):2091-102. PubMed ID: 24891317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.
    van der Heijde D; Da Silva JC; Dougados M; Geher P; van der Horst-Bruinsma I; Juanola X; Olivieri I; Raeman F; Settas L; Sieper J; Szechinski J; Walker D; Boussuge MP; Wajdula JS; Paolozzi L; Fatenejad S;
    Ann Rheum Dis; 2006 Dec; 65(12):1572-7. PubMed ID: 16968715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Grassnickel L; Rudwaleit M; Sieper J; Braun J
    Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide reduces recurrence of ankylosing spondylitis in patients following discontinuation of etanercept.
    Deng X; Zhang J; Zhang J; Huang F
    Rheumatol Int; 2013 Jun; 33(6):1409-13. PubMed ID: 23143621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Etanercept 25 mg Once Weekly as Effective as 50 mg at Maintaining Response in Patients with Ankylosing Spondylitis? A Randomized Control Trial.
    Yates M; Hamilton LE; Elender F; Dean L; Doll H; MacGregor AJ; Thomas J; Gaffney K
    J Rheumatol; 2015 Jul; 42(7):1177-85. PubMed ID: 26034151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept.
    Davis JC; Van der Heijde DM; Dougados M; Braun J; Cush JJ; Clegg DO; Inman RD; de Vries T; Tsuji WH
    J Rheumatol; 2005 Sep; 32(9):1751-4. PubMed ID: 16142873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etanercept in the longterm treatment of patients with ankylosing spondylitis.
    Dijkmans B; Emery P; Hakala M; Leirisalo-Repo M; Mola EM; Paolozzi L; Salvarani C; Sanmarti R; Sibilia J; Sieper J; Van Den Bosch F; van der Heijde D; van der Linden S; Wajdula J
    J Rheumatol; 2009 Jun; 36(6):1256-64. PubMed ID: 19411393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice.
    Escudero-Vilaplana V; Ramírez-Herráiz E; Alañón-Plaza E; Trovato-López N; García-Vicuña R; Carreño-Pérez L; Morell-Baladrón A; Sanjurjo-Sáez M
    Int J Clin Pharm; 2015 Oct; 37(5):808-14. PubMed ID: 25910480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis.
    Martín-Mola E; Sieper J; Leirisalo-Repo M; Dijkmans BA; Vlahos B; Pedersen R; Koenig AS; Freundlich B
    Clin Exp Rheumatol; 2010; 28(2):238-45. PubMed ID: 20483046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.
    Davis JC; van der Heijde DM; Braun J; Dougados M; Cush J; Clegg D; Inman RD; Kivitz A; Zhou L; Solinger A; Tsuji W
    Ann Rheum Dis; 2005 Nov; 64(11):1557-62. PubMed ID: 15843448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and MRI response to dose reduction of an etanercept-biosimilar for hip arthritis in patients with ankylosing spondylitis: an observational, retrospective cohort study.
    Huang ZX; Deng WM; Guo X; Huang ZP; Huang YK; Lin CL; Li TW
    Clin Rheumatol; 2019 Jun; 38(6):1595-1604. PubMed ID: 30746581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study.
    Cantini F; Niccoli L; Cassarà E; Kaloudi O; Nannini C
    Biologics; 2012; 6():201-6. PubMed ID: 22904612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.